NIH Reporter #5R01CA257251-05

NIH Grant for CDK4/6-targeted PROTAC Development for Leukemia

This opportunity is issued by the National Cancer Institute (NCI), part of the NIH, for research organizations to develop and test CDK4/6-targeted PROTACs for treating Philadelphia chromosome-positive (Ph+) and Ph1-like acute lymphoblastic leukemia (ALL). - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Primary location: Thomas Jefferson University, Philadelphia, PA - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Products/Services Requested: - Pre-clinical research services for CDK4/6-targeted PROTACs - Includes development and in vivo testing of therapeutic agents for Ph+ and Ph1-like ALL in mouse models - Unique/Notable Requirements: - Expertise in cancer research, drug development, and pre-clinical animal studies - Focus on high-risk B-ALL and innovative therapeutic approaches - Estimated Contract Value: - Approximately $631,337 for the project duration - Period of Performance: - Covers a multi-year period (2025-2027)

Description

This NIH grant opportunity focuses on developing and testing CDK4/6-targeted PROTACs for the treatment of Ph+ and Ph1-like acute lymphoblastic leukemia (ALL). The project involves pre-clinical studies, including in vivo testing in mouse models, aiming to develop more effective therapeutic agents for high-risk B-ALL. The award amount is approximately $631,337 for the period 2025-2027. The solicitation is open for applications with an expected award date of June 17, 2025.

View original listing